PART I. Snapshot
My Implied Share Price: $29.32
| Symbol | Price | Weight |
| Cash | 1.00 | 38.31% |
| MOV | 19.47 | 8.74% |
| Stock Options | 1.00 | 5.29% |
| AII | 19.67 | 3.71% |
| IIPR | 57.3 | 3.60% |
| CROX | 86.45 | 2.87% |
| SPB | 56.88 | 2.81% |
| INTC | 24.49 | 2.20% |
| JAKK | 17.6 | 2.13% |
| LNC | 42.11 | 2.12% |
| LEN | 141.88 | 2.04% |
| VZ | 44.38 | 1.99% |
| MKL | 1912.13 | 1.72% |
| MOH | 174.65 | 1.57% |
| CNC | 28.98 | 1.56% |
| TGT | 93.17 | 1.51% |
| NVO | 55.23 | 1.24% |
| GRAB | 5.16 | 1.16% |
| PETS | 3.05 | 1.09% |
| UBER | 90.99 | 0.98% |
| FLR | 41.57 | 0.93% |
| YALA | 7.57 | 0.88% |
| PINS | 37.94 | 0.82% |
| IBTA | 27.51 | 0.79% |
| BG | 84.33 | 0.76% |
| LULU | 167.8 | 0.75% |
| BBBY | 9.88 | 0.71% |
| CRCT | 5.93 | 0.69% |
| GRBK | 73.38 | 0.66% |
| DHI | 181.8 | 0.65% |
| WU | 8.84 | 0.63% |
| GM | 58.27 | 0.63% |
| PYPL | 68.26 | 0.61% |
| ACI | 19.06 | 0.60% |
| LYFT | 16.66 | 0.60% |
| FLO | 14.81 | 0.53% |
| BWEN | 2.05 | 0.46% |
| PZZA | 48.24 | 0.43% |
| GLDD | 11.73 | 0.37% |
| DOLE | 13.56 | 0.37% |
| HCC | 60.71 | 0.27% |
| UNFI | 28.95 | 0.23% |
Updated: September 7, 2025
PART II. Significant Developments
I significantly increased my portfolio with a cash deposit this month. This did not impact the Implied Share Price, as I implicitly bought more shares at $28.53 per share from myself, which was the fair value, if not slightly above. However, it would have doubled the portfolio’s size and increased the cash position. I also made some other minor adjustments to the portfolio after the cash deposit.
PART III. Segment Review
This month I’m reviewing Segment 9, health-related subsidiaries.
In the Health Segment I own 1. Molina Healthcare, Inc. (MOH), 2. Centene Corporation, (CNC), and 3. Novo Nordisk A/S (NVO). I also own LEAP stock options on NVO.
MOH, CNC, and NVO
I am very excited to have three awesome healthcare companies added to the portfolio. For Novo Nordisk, I believe the price is extremely undervalued, and I still believe in the potential that the weight loss drugs have for the future. The positive impact that they can have in regards to helping treat so many diseases, and the posible number of people that will benefit from the use of them made me a believer. Also, with the expansion of potential weight-loss pills and other new drugs that are considered to be under development, I think this company has a bright future.
At the time of purchase, the option prices were so low, and the share price of this company was low as well. I’m not huge on health stocks, generally, but all three of these, including an insurance companies appear to be no-brainers. Nothing is guaranteed, but with no significant changes foreseeable for the healthcare insurance industries, I went ahead and place a good portion allocation for this segment of my portfolio, which I referred to the health segment.